Theravance’s Revefenacin On Track For 2017 Filing With Success In Two Pivotal Trials
Partnered with Mylan to bring the first once-daily nebulized LAMA bronchodilator to market for COPD, Theravance reports statistical significant in two Phase III studies and now awaits data expected next year from an open-label safety study.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Mylan could tap respiratory product experience to develop line extensions to the homeopathic product, now seen as the centerpiece of its US consumer business.
Mylan will spend $45m up front and pay up to $220m in milestone fees plus royalties to co-develop TD-4208, Theravance Biopharma's once-daily long-acting muscarinic antagonist (LAMA) delivered by a nebulizer for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.